SUBCELLULAR-LOCALIZATION OF THE VIF PROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1

被引:115
|
作者
GONCALVES, J
JALLEPALLI, P
GABUZDA, DH
机构
[1] DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115
[2] HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115
[3] HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115
关键词
D O I
10.1128/JVI.68.2.704-712.1994
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Vif (viral infectivity factor) protein of human immunodeficiency virus type 1 (HIV-1) has been shown to dramatically enhance the infectivity of HIV-1 virus particles during virus production. The subcellular localization of Vif was examined to elucidate cellular pathways which may be important far Vif function. Indirect immunofluorescence staining of Vif demonstrated a diffuse cytoplasmic distribution and showed that most Vif was not associated with the Golgi complex, a proposed site of localization (B. Guy, M. Geist, K. Dott, D. Spehner, M.-P. Kieny, and J.-P. Lecocq, J. Virol. 65:1325-1331, 1991). Subcellular fractionation of transfected COS cells and HIV-1-infected Jurkat and CEM cells demonstrated that Vif is a cytoplasmic protein which exists in both a soluble cytosolic form and membrane-associated form. The membrane-associated form of Vif is a peripheral membrane protein which is tightly associated with the cytoplasmic side of cellular membranes. The C terminus of Vif was required for the stable association of Vif with membranes. The C terminus was also essential for Vif function, suggesting that the association of Vif with membranes is likely to be important for its biological activity. The highly conserved regions at residues 103 to 115 and 142 to 150 were important for Vif function but did not affect membrane association, indicating that these regions are likely to be important for other, as-yet-unknown functions.
引用
收藏
页码:704 / 712
页数:9
相关论文
共 50 条
  • [41] VIRAL DYNAMICS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    SHAW, GM
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 : S83 - S83
  • [42] STIMULATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 EXPRESSION BY CERAMIDE
    PAPP, B
    ZHANG, DZ
    GROOPMAN, JE
    BYRN, RA
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (07) : 775 - 780
  • [43] INFECTIOUS DECAY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN PLASMA
    MOUDGIL, T
    DAAR, ES
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (01): : 210 - 212
  • [44] VIRAL DYNAMICS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    WEI, XP
    GHOSH, SK
    TAYLOR, ME
    JOHNSON, VA
    EMINI, EA
    DEUTSCH, P
    LIFSON, JD
    BONHOEFFER, S
    NOWAK, MA
    HAHN, BH
    SAAG, MS
    SHAW, GM
    [J]. NATURE, 1995, 373 (6510) : 117 - 122
  • [45] MOLECULAR-BIOLOGY OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    HASELTINE, WA
    [J]. FASEB JOURNAL, 1991, 5 (10): : 2349 - 2360
  • [46] QUANTITATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION KINETICS
    DIMITROV, DS
    WILLEY, RL
    SATO, H
    CHANG, LJ
    BLUMENTHAL, R
    MARTIN, MA
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (04) : 2182 - 2190
  • [47] BASIC FEATURES OF THE NUCLEOCAPSID OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    DARLIX, JL
    ROQUES, BP
    [J]. M S-MEDECINE SCIENCES, 1993, 9 (8-9): : 952 - 958
  • [48] HYDROXYCHLOROQUINE TREATMENT OF PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    SPERBER, K
    LOUIE, M
    KRAUS, T
    PRONER, J
    SAPIRA, E
    LIN, S
    STECHER, V
    MAYER, L
    [J]. CLINICAL THERAPEUTICS, 1995, 17 (04) : 622 - 636
  • [49] MALIGNANCIES IN CHILDREN WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    ARICO, M
    CASELLI, D
    DARGENIO, P
    DELMISTRO, AR
    DEMARTINO, M
    LIVADIOTTI, S
    SANTORO, N
    TERRAGNA, A
    [J]. CANCER, 1991, 68 (11) : 2473 - 2477
  • [50] MOLECULAR INSIGHTS INTO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PATHOGENESIS
    FEINBERG, MB
    GREENE, WC
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1992, 4 (04) : 466 - 474